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http://dxObjective: Myocardial infarction (MI) can lead to irreversible adverse left ventricular remodeling resulting in
subsequent severe dysfunction. The objective of this study was to investigate the potential for biodegradable,
elastomeric patch implantation to positively alter the remodeling process after MI in a porcine model.
Methods: Yorkshire pigs underwent a 60-minute catheter balloon occlusion of the left circumflex artery. Two
weeks after MI animals underwent epicardial placement of a biodegradable, porous polyurethane (poly(ester
urethane)urea; PEUU) patch (MIþPEUU, n¼ 7) or sham surgery (MIþsham, n¼ 8). Echocardiography before
surgery and at 4 and 8 weeks after surgery measured the end-diastolic area (EDA) and fractional area change (%
FAC). All animals were humanely killed 8 weeks after surgery and hearts were histologically assessed.
Results: At 8 weeks, echocardiography revealed greater EDA values in the MIþsham group (23.6  6.6 cm2,
mean  standard deviaation) than in the MIþPEUU group (15.9 2.5 cm2) (P<.05) and a lower%FAC in the
MIþsham group (24.8 7.6) than in the MIþPEUU group (35.9 7.8) (P<.05). The infarcted ventricular wall
was thicker in the MIþPEUU group (1.56  0.5 cm) than in the MIþsham group (0.91  0.24 cm) (P<.01).
Conclusions: Biodegradable elastomeric PEUU patch implantation onto the porcine heart 2 weeks post-MI at-
tenuated left ventricular adverse remodeling and functional deterioration and was accompanied by increased
neovascularization. These findings, although limited to a 2-month follow-up, may suggest an attractive clinical
option to moderate post-MI cardiac failure. (J Thorac Cardiovasc Surg 2013;146:391-9)E
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The Journal of Thoracic and Casymptomatic congestive heart failure over time. Regional
structural changes in left ventricular (LV) remodeling after
MI can lead to global LV geometric change, which contrib-
utes to an increase in LV wall stress1 and mitral regurgita-
tion.2 Epidemiologically, survival after MI is related to the
magnitude of LV dilatation.3 Thus, therapies designed to at-
tenuate postinfarct LV dilatation, by pharmacologic or sur-
gical means, have been pursued to alleviate postinfarction
morbidity and mortality in adverse remodeling after MI.
A spectrum of surgical procedures, cardiac resynchroniza-
tion therapy (biventricular pacing),4 or pharmacologic therapy
(eg, angiotensin-converting enzyme inhibitors and beta-
blockers)5 have been applied in the clinical setting after MI
in an effort to limit adverse LV remodeling. Surgical ap-
proaches include surgical ventricular restorationwith anendo-
cardial patch such as the Dor procedure6 or ventricular
wrapping with an epicardial patch.7 The patches used in these
procedures, however, have beenmade fromnonbiodegradable
materials with low elasticity. Such materials raise concerns
about a chronic foreign-body response, potentially leading
to difficulties in reoperation, or LV diastolic failure owing to
nonelastic encapsulation.Microbial infection is also a concern
that arises when implanting a permanent foreign body.
In animal models for ischemic cardiomyopathy, a variety
of biodegradablematerials as interventional therapeutic strat-
egies have been investigated, including epicardial patches
with and without cellular constituents,8-12 intramyocardialrdiovascular Surgery c Volume 146, Number 2 391
Abbreviations and Acronyms
aSMA ¼ a-smooth muscle actin
EDA ¼ end-diastolic area
EF ¼ ejection fraction
ESA ¼ end-systolic area
%FAC ¼ fractional area change
LV ¼ left ventricular (ventricle)
LVEDV ¼ left ventricular end-diastolic volume
LVESV ¼ left ventricular end-systolic volume
MI ¼ myocardial infarction
PEUU ¼ poly(ester urethane)urea
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Shydrogel injectables,13,14 and intracoronary injectables.15We
have previously reported that an elastic, biodegradable car-
diac patch,without cells, prevents cardiac remodeling and im-
proves LV function after MI with a rodent model.8 However,
whether this relatively straightforward approach would serve
to similarly prevent LV remodeling in a more clinically rele-
vant large animal model has not been addressed. Namely, the
efficacy of epicardial patch plasty with a degradable material
in a large animal model has not been addressed to date. Our
objective herewas to examine the efficacy of a porous, elastic
epicardial patch made from biodegradable polyurethane
(poly[ester urethane]urea; PEUU), which was designed to
have properties appropriate for the cardiovascular system, us-
ing a porcine ischemia–reperfusion MI model.MATERIALS AND METHODS
Animal Preparation
Twenty-five healthy female crossbred Yorkshire swine, 4 to 5 months
old and weighing 23  6 kg, were used in this study. Porcine LV infarcts
were created by catheter-based balloon occlusion for 60 minutes and re-
perfusion of the proximal circumflex artery. Two weeks after MI, patch
placement or sham surgery was performed. Before surgery, animals that
survived the infarct procedure and had an infarct size meeting the selec-
tion criterion, animals with a risk area more than 25% of LV free wall,
were randomly assigned to either the PEUU patch placement
(MIþPEUU) or sham surgery (MIþsham) group, and were screened by
echocardiography to obtain the baseline data. The animal protocol used
in the study was approved by the Institutional Animal Care and Use Com-
mittee of the University of Pittsburgh (No. 0612885). All animals received
humane care in compliance with the ‘‘Guide for the Care and Use of Lab-
oratory Animals’’ published by the National Institutes of Health (1996,
National Academy Press, Washington, DC). Arterial blood pressure, pulse
oximetry, and electrocardiograms were continuously monitored through-
out the procedures.
Catheterization for LV Ischemia–Reperfusion
Protocol
The animals were anesthetized with ketamine (20 mg/kg) and xylazine
(2 mg/kg) administered intramuscularly, followed by intubation and main-
tenance by mechanical ventilation with oxygen supplemented with 2.0%
isoflurane. After placement of the animal in a supine position, the femoral
artery was percutaneously cannulated using a 6F arterial sheath with a Sel-
dinger technique under sterile conditions. A bolus of 60 mg/kg heparin
and 2 mg/kg of amiodarone was intravenously administered and392 The Journal of Thoracic and Cardiovascular Surgamiodarone was then continuously infused at 1 mg/min during the proce-
dure to prevent lethal ventricular arrhythmias associated with this
model.16 The ischemia–reperfusion model, which is commonly used in
porcine studies of post-MI therapy,17 was used. The left main coronary
artery was selectively engaged using an AL 1 guide catheter (6F; Cordis
Corp., Miami, Fla). Using a 3.5 3 12 mm coronary dilatation balloon
catheter (Guidant, Santa Clara, Calif), the proximal left circumflex artery
was occluded for 60 minutes by balloon inflation (Figure 1).16 Direct-
current cardioversion was performed when sustained ventricular tachycar-
dia or ventricular fibrillation was observed. The animals were then
allowed to recover from anesthesia and returned to their housing facility.
Buprenorphine (0.05 mg/kg) and cefazolin (30 mg/kg) were administered
intramuscularly 2 times per day for 3 days after the procedure. All ani-
mals were screened by echocardiography for infarct size as estimated
by the percentage of risk area (severe hypokinetic, akinetic, or dyskinetic
regions) to the LV free wall area. Animals with a risk area of less than
25% of the LV free wall were excluded from the analysis and humanely
killed immediately after echography.Scaffold Fabrication
PEUUwas synthesized according tomethods previously described from
polycaprolactone (PCL, Mn ¼ 2000, Sigma), diisocyanatobutane (BDI,
Sigma), and putrescine.18 A detailed methodology for scaffold fabrication
and characterization is provided in the online data supplement.
Epicardial Patch Placement Surgery
Two weeks after the MI, the animals were sedated with ketamine
(20 mg/kg) and xylazine (2 mg/kg) given intramuscularly, intubated, and
anesthesia was provided with oxygen with 1.5% inhaled isoflurane. Lido-
caine (10 mg/kg) was given to prevent arrhythmias. The heart was exposed
through an anterolateral thoracotomy at the fourth intercostal level, and the
infarcted cardiac surface was lightly scraped with a surgical knife to intro-
duce blood into the porous PEUU patch and to aid in adhering the entire
patch surface onto the surface of the epicardium. The patch was then se-
cured by continuous running suture with 6-0 polypropylene in the PEUU
patch group so that the patch covered the infarct area. In the sham surgery
group the heart was lightly scraped but no material was implanted. The
wound was closed with 4-0 polyglactin absorbable sutures. During the pro-
cedure, bupivacaine (0.2 mL/kg) was locally injected into the thoracic wall.
The animals were then allowed to recover and returned to their housing
facility. Buprenorphine (0.05 mg/kg) and cefazolin (30 mg/kg) were
administered intramuscularly 2 times per day for 3 days after surgery for
postoperative analgesic treatment and for prophylaxis of surgical site infec-
tion, respectively. Echocardiography was performed on each animal at the
4- and 8-week time point after surgery under the anesthesia program
described above, but without intubation. All animals were humanely killed
at the 8-week time point with potassium chloride bolus dosing (50 mEq/kg)
under anesthesia.
Echocardiography
Transthoracic echocardiograms were obtained 2 week after MI as
a baseline, 4 weeks after surgery, and at the time of humane killing (8
weeks after surgery) using a Sonos 1500 platform (Hewlett-Packard Com-
pany, Palo Alto, Calif) equipped with a 2.5-MHz transducer. Short-axis
views of the LV at the level of the papillary muscle were obtained from
a right parasternal approach. The end-diastolic (EDA) and end-systolic
(ESA) LV internal cavity areas were determined offline by tracing the en-
docardial border using OsiriX image processing application v.3.7.1. The
LV fractional area change (%FAC) was calculated according to the fol-
lowing equation:
%FAC ¼ EDAESA
EDA
3 100ery c August 2013
FIGURE 1. Ischemia–reperfusion (I-R) injury and patch implantation protocol. Female swine underwent left circumflex artery (LCx) occlusion for 60 min-
utes followed by reperfusion (A to D). Black, white, and yellow arrows indicate LCx, occlusion balloon, and completely occluded LCx, respectively. *Left
anterior descending (LAD) coronary artery and diagonal branches. The electrocardiogram during the LCx occlusion procedure showed elevated S-T segment
and inverted Twave in lead II (D). The study protocol applied is shown in pare E. Circular poly(ester urethane)urea (PEUU) patches were implanted 2 weeks
after I-R injury (F). p, Implanted PEUU patch; laa, left atrial appendage; ap, apex of heart. Macroscopic appearance for the PEUU patch implanted heart at
the 8-week end point (G). The black dashed line indicates estimated edge of the remnant implanted material.
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SLV volumes were estimated using the following formula of Teichholz to
derive LV end-systolic volume (LVESV), LV end-systolic volume
(LVEDV), and LV ejection fraction (EF):
V ¼ 7:0
2:4 þ D 3 D
3
where VandD are LV volume and diameter and weremeasured byM-mode
echocardiography at end-systolic or end-diastolic cardiac phase. Echocar-
diography and offline tracing processing were done by the operators, who
were blinded to the treatment assignment.Postmortem Study
After the animals were humanely killed, adhesive noncardiac tissue was
removed and the hearts were dissected. The hearts were cut along the lon-
gitudinal axis in slices 1-cm thick. The wall thickness of the risk area was
measured with a digital caliper (Fisher Scientific, Pittsburgh, Pa) from 10
random locations to obtain an average for each sample. Tissue samples
from the risk area were either fixed in 4% formalin and paraffin-
embedded for hematoxylin and eosin staining or fixed in 4% phosphate-
buffered paraformaldehyde for 4 hours, followed by immersion in 30%
sucrose solution for at least 2 days for immunostaining. Samples fixed
with paraformaldehyde were stained immunohistochemically with anti-
bodies against a-smooth muscle actin (aSMA) (1:200; Sigma Chemical
Co, St Louis, Mo) or CD31 (1:200; Serotec, Raleigh, NC). Nuclei were
stained with 40,6-diamidino-2-phenyindole (1:10,000; Sigma). SlidesThe Journal of Thoracic and Cawere examined with an Olympus BX51 microscope and images captured
digitally (Olympus America, Inc, Center Valley, Pa).
For each retrieved sample from the infarct area, 10 different micro-
scopic fields at 4003magnification for CD31-positive structures were pho-
tographed. To quantify the vascular density, the number of CD31-positive
tubular structures was measured using digital image processing ImageJ
software (National Institutes of Health, Bethesda, Md).
Statistical Analysis
Data are reported as mean standard deviation. For comparisons in the
wall thickness and vascular density, the Student t test was performed. Two-
way repeated analysis of variance followed by the Tukey test was applied to
multiple comparisons in the EDA and %FAC analysis. All statistical
evaluations were performed using SigmaStat (Systat Software Inc, Point
Richmond, Calif).RESULTS
Material Characteristics
The PEUU patch appeared white and spongy (Figure 2,
A) with a pore size ranging from 30 to 100 mm (40  22
mm, Figure 2, B) and a porosity of 86%  2%. The patch
had a peak tensile strength of 307 87 kPa with a peak ten-
sile strain of 103% 13% and an initial modulus of 704
100 kPa. A cyclic tensile test was performed to evaluaterdiovascular Surgery c Volume 146, Number 2 393
FIGURE 2. Macroscopic view of the porous PEUU patch (A) fabricated by thermally induced phase separation. Scanning electron micrograph (B) dem-
onstrates the pore structure of the scaffold. Typical cyclic tensile response curves (C), with a maximum 30% strain, show a lack of obvious unrecoverable
scaffold distention after 10 cycles.
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Spatch elasticity. As shown in Figure 2, C, a large hysteresis
loop in the first cycle was observed, and in the next 9 cycles,
smaller and overlapped hysteresis loops were recorded. No
obvious unrecoverable deformation was detected.Postoperative Course and Gross Observations
A total of 25 swine underwent the coronary occlusion pro-
cedure. Therewere 7 (28%) deaths during the 60-minute left
circumflex occlusion procedure because of refractory ven-
tricular fibrillation against direct-current shock. After the
catheterization, 2 animalswere excludedowing to their small
lesions at risk. One animal was lost in the MIþsham group
because of sudden death 2 weeks after the sham surgery.
The final analysis thus included 7 animals in the MIþPEUU
group and 8 in the MIþsham group (Table E1). The PEUU
patch material tolerated suture line tension and was safely
implanted with continuous suture (Figure 1, F). During sys-
tole, the elastic patch was observed towrinkle slightly, while
during diastole, qualitative stretching could be seen (Video
1). At 8 week after implantation, the PEUU patch was found
to have formed no strong adhesions with the chest wall, and
the region where the remnant patch was located was covered
with connective tissue (Figure 1, G, Video 2).Tissue Thickness in the Risk Zone
The LV wall thickness of the risk zone was measured im-
mediately after death for both the MIþPEUU (n ¼ 7) and
MIþsham groups (n ¼ 8). The thickness of the PEUU
patched wall was significantly greater than for the sham394 The Journal of Thoracic and Cardiovascular Surgsurgery wall (1.56  0.30 vs 0.91  0.24 cm, PEUU vs
sham, P<.01) (Figure 3).Histology and Immunochemistry
Samples for histologic assessment were obtained from all
animals for both the MIþPEUU and MIþsham groups. The
wall onto which the PEUU patch was placed was character-
ized by several distinct regions. From the endocardial side,
some preserved myocardial tissue was evident; above this
was a vascularized region that transitioned into a layer
with diffuse cells that stained positively for aSMA. Above
the layer with aSMA-stained cells, the remnant PEUU
material was apparent and was infiltrated with cells also
staining positively for aSMA. The remnant PEUU material
appears as white voids or fragments in Figure 4, A, region p,
and along the top right corner of Figure 4, B. At the epicar-
dial surface, connective tissue was present above the patch
(Figure 4, A-G). In contrast, the untreated, infarcted LVwall
was composed of 2 regions: a layer of scar tissue that had
a relatively low density of aSMA-expressing cells, and,
near the endocardium, some preserved myocardial tissue
comparable with that seen in the hearts receiving the patch
(Figure 4, H and I). Comparing the region above the pre-
served myocardial tissue in the MIþsham hearts with the
similar region above this tissue in the MIþPEUU group,
the latter group had a significantly greater density of vascu-
lar structures with a wide variety of diameters compared
with the MIþsham group (157  16 vs 83  8 per mm2,
PEUU vs sham; P<.01) (Figure 4, J).ery c August 2013
FIGURE 3. Left ventricular wall thickness in the risk zone. Representative photographic images of ventricular transection for the poly(ester urethane)urea
(PEUU) patched wall (A) and sham surgery wall (B) at the 8-week time point. Thewhite and yellow arrows represent implanted PEUU patch and suture line
for patch implantation, respectively. Epi, Epicardial site; end, endocardial site. Scale bars: 1 cm. The PEUU patched wall (n ¼ 7) was significantly thicker
than the sham surgery wall (n ¼ 8) (C). *P<.01.
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SEchocardiography
Transthoracic echocardiograms were obtained in all ani-
mals in the MIþPEUU group (n ¼ 7) and MIþsham group
(n ¼ 8) at all 3 time points. One case of trivial mitral regur-
gitation was observed in the MIþsham group at the 8-week
time point. A significant interaction was found to exist
between the groups and observed time points (P< .05).
The MIþPEUU group did not experience a significant
change in either EDA or %FAC after patch implantation
at any of the time points; the EDA of the MIþsham group
at 4 and 8 weeks was significantly increased and the %
FAC at 8 weeks was decreased versus the 0-week pointThe Journal of Thoracic and Cawhen compared for time factor within group. There were
no statistically significant differences in the EDA and %
FACbetween the 2 groups at the time of surgery and 4weeks
after surgery. In contrast, 8 weeks after surgery, the EDA in
theMIþshamgroupwas greater than that for theMIþPEUU
group (15.9  2.5 vs 23.6  6.6 cm2, PEUU vs sham;
P<.05) and the%FAC in theMIþPEUU group was greater
than that of theMIþshamgroup (35.9 7.8 vs 24.8 7.6%;
P<.05) (Figure 5,A toF). Consistently, LV volume analysis
using parameters estimated by LV inner diameters
revealed greater LVESV (113  47 cm3) and LVEDV (164
 77) in the MIþsham group than those (54  10 and 102rdiovascular Surgery c Volume 146, Number 2 395
FIGURE 4. Hematoxylin and eosin staining and immunostaining for a-smooth muscle actin (aSMA) and CD31. The poly(ester urethane)urea (PEUU)
patched wall exhibited an aSMA rich layer (s) beneath the implanted PEUU patch (p). Below the aSMA rich layer was a vascular rich layer (v) and
then a myocardial remnant (r) region at the endocardial side (A). epi, Epicardial site; end, endocardial site. *Connective tissue formed above the implanted
PEUU. The dashed lines approximate each boundary. Looking at a higher magnification of the boundary area between the PEUU patch and aSMA rich layer
showed that the PEUU had partially degraded and cellular infiltration had occurred with aSMA-positive cells (B and C). The junction between aSMA and
vascular rich layers is highlighted in (D and E) and the center of the vascular rich layer is showed in parts F and G. The hematoxylin and eosin staining in the
MIþsham group is shown in part I. The aSMA-positive structure and vessels in theMIþsham group are shown in part H. Capillary density was greater in the
MI-PEUU group than in the MIþsham group (*P<.01) (J). Scale bars: 200 mm.
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S 24, respectively) in the MIþPEUU group (P<.05). The
MIþsham group had decreased EF at 4 and 8 weeks (30%
 4% and 30%  7%, respectively) than the MIþPEUU
group (46  9 and 45  13, respectively) (P < .05)
(Figure 5, G to I).
DISCUSSION
The results demonstrated that PEUU patch implantation
prevented LV adverse remodeling and cardiac functional
loss for an 8-week period after placement over an ische-
mia–reperfusion injury in a porcine model. The implanted
PEUU patch partially degraded in this period and an
aSMA-positive cellular infiltrate in the remnant patch ma-
terial was observed. Below the patch, similarly labeled
cells were observed together with significantly increased
neovascularization and LV wall thickening, the latter of
which would theoretically contribute to decreased wall
stress explained by the LaPlace law. These findings are
consistent with our previous study using a smaller patch
of the same material in a rodent ischemic cardiomyopathy
model.8396 The Journal of Thoracic and Cardiovascular SurgWhereas nonbiodegradable, biventricular wrapping de-
vices have already been evaluated in the clinic,7 a localized,
elastic biodegradable patch has theoretical advantages over
these earlier approaches. Whole epicardial wrapping raises
concerns about reoperation complexity owing to extensive
pericardial adhesions and the potential for coronary
blood flow impairment.19 Furthermore, the placement of
a permanent foreign body is associated with a chronic infec-
tion risk and potential calcification nidus. A regional,
degradable patch plasty approach would limit such concerns
and, through the selectionof an appropriate degradable elastic
polymer, could offer the potential to control the degradation
rate20 and to incorporate pharmaceuticals for localized con-
trolled release.21 Although several studies have reported a va-
riety of biodegradable, epicardial patch approaches to limit
LV remodeling after ischemic injury,8-12 these approaches
have used cellular components and few have been
translated to themore clinically relevant large animalmodels.
There are 2 notable earlier reports in which regional
epicardial patch plasty was evaluated in a large animal
model, although both reports used nonbiodegradable andery c August 2013
FIGURE 5. Temporal echocardiographic assessment for end-diastolic area (EDA) and fractional area change (%FAC) after the patch implantation or sham
surgery. Representative M-mode (A and B) and short-axis view of the left ventricle (C and D) at the 8-week time point. Scale bars: 5 cm. The broken lines in
parts C and D indicate the inner surface of the left ventricle. The inset in part D shows trivial mitral regurgitation (yellow arrow), a case observed in the
MIþsham group. The EDA was significantly greater in the MIþsham than in the MIþPEUU group (E) and %FAC was significantly preserved in the
PEUU versus the MIþsham group (n ¼ 7 or 8 for each group) (F). *P<.05 between groups at 8-week time point; yP<.05 versus just before implantation
(Pre)within group. The volumetric analysis using estimates derived from left ventricular diameters showed greater increases in left ventricular volume in the
MIþsham group at the 8-week point (G and H) and preserved ejection fraction in the MIþPEUU group at 4- and 8-week points (I). LVESV, Left ventricular
end-systolic volume; LVEDV, left ventricular end-diastolic volume; ns, not significant.
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Snonelastic synthetic materials.19,22 Kelley and colleagues22
placed a commercial knitted polypropylene mesh over the
anticipated LV infarct region before MI and showed limited
LV dilation and functional deterioration, such as LV end-
diastolic pressure, in an ovine model at 8 weeks. Although
the results from this early study were encouraging, the clin-
ical relevance of patch placement before MI raised some
questions regarding the likely effects of a patch placed atThe Journal of Thoracic and Caa more clinically relevant time after MI. More recently,
Liao and colleagues19 placed a composite synthetic mesh
made of a polypropylene mesh inner layer and expanded
polytetrafluoroethylene outer layer, with the expanded pol-
ytetrafluoroethylene side toward the pericardium to mini-
mize the risk of pericardial adhesions. The patch was
used in a porcine model 8 weeks after MI to evaluate the
impact on the chronic phase of LV remodeling. Using anrdiovascular Surgery c Volume 146, Number 2 397
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Selegant array of magnetic resonance imaging and catheter-
based hemodynamic analysis, these investigators showed
that regional, nonbiodegradable patch placement attenuated
LV dilation, increased LV wall thickness, and improved LV
ejection fraction andþdP/dt. At 12 weeks after patch place-
ment, significant LV dilation was observed, in contrast to
our findings. The timing of patch placement (2 weeks after
MI in our study vs 8 weeks in their study) and whether the
peri-infarct (border) zone was covered with material (the
PEUU patch covered both the risk and border zone) might
account for the discrepancy in the LV dilation after patch-
ing. Both of these earlier reports provide encouraging re-
sults regarding the potential for regional patch plasty and
raised the question whether such benefits could be achieved
without placement of a permanent foreign body on the epi-
cardium and whether an elastic patch material might not be
better suited mechanically for the task of altering the me-
chanical environment of the remodeling ischemic LV wall.
The advantage of using an elastic patch material such as
PEUU as opposed to a stiff polymer has not been definitely
shown, although there is reason to believe that the mechan-
ical properties of the patch material matter. Using a rodent
model, we8 have shown that an unpatched infarcted LV
wall had the least compliance, whereas the PEUU-patched
LV was significantly more compliant, better approximating
the passiveproperties of healthy cardiac tissue.Also, in com-
paring an expanded polytetrafluoroethylene versus a PEUU
patch applied to an infarcted rat LV, the PEUU patched wall
was thicker and those animals had significantly improved
functional reserve under dobutamine stress.23 It is speculated
that the elastic PEUU material allows myofibers in both the
risk zone and border zone to stretch during diastole while
also providing a reduction in wall stress. The advantage of
elasticity and distensibilty in the infarcted LV has been im-
plicated previously, wherein improvement in LV function
was attributed to augmented elastin network formation by
mononuclear cell injection24 or elastin gene therapy.25
Even though the original mechanical properties of the ap-
plied PEUU patch will necessarily be reduced as material
degradation proceeds, the induced tissue formed beneath
the patch increases wall thickness, leading to reduction in
wall stress, and in the ratmodel, is mechanically softer under
tensile loading than the unpatched infarcted wall.8
Several limitations of the current report should be men-
tioned. Although patch placement was associated with an
alteration in the extent of adverse LV remodeling, this inter-
vention becomes the starting point of an altered remodeling
process. Hence, a longer follow-up period after patch
implantation would provide additional insights into the
influence of epicardial patch plasty on extended functional
preservation and LVmorphology. Although patch mechani-
cal support properties will be lost earlier than complete
material degradation, an end point after traces of thematerial
are completely removed would elucidate whether the398 The Journal of Thoracic and Cardiovascular Surgtemporal LV support effects on ventricular geometry endure
for a prolonged period. Second, detailed assessments could
be performed using several techniques to provide better in-
sight into the nature of functional benefits associated with
the procedure: echocardiography to track regional LV wall
motion and provide more detailed geometric analysis (eg,
sphericity index); magnetic resonance imaging to investi-
gate LV geometry and provide accurate LV volumes with
the cardiac cycle; positron emission tomography/magnetic
resonance imaging to assess cardiac metabolism; and inva-
sive hemodynamic monitoring to obtain functional parame-
ters such as dP/dt max or preload/afterload-corrected
echocardiographic evaluation. Third, postmortem infarct
size and fibrosis measurements are lacking in the study.
Finally, this study does not address the optimal timing for
patch implantation or the optimal rate for material degrada-
tion. Performing the patch plasty procedure sooner after MI
(eg, within days as opposed to 2 weeks) may produce better
functional preservation. Whether a faster or slower degrad-
ing patch would provide improved benefit is also undeter-
mined, as is the optimal elastic stiffness of the material to
be applied.
In conclusion, PEUU patch implantation prevented LV
dilatation, preserved contractile function, and improved
the retention of wall thickness in the infarcted LV wall.
Improved vascularity was observed in the patched LV
wall. These data in a large animal model are consistent
with our previous results in small animals and suggest
that PEUU patch placement may be efficacious for cardio-
myoplasty of the chronically infarcted LV wall by altering
the adverse remodeling process and, at least temporarily,
preserving myocardial function.
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E-MATERIALS AND METHODS
Scaffold Fabrication
PEUU was synthesized according to methods previously described
from polycaprolactone (PCL, Mn ¼ 2000; Sigma), diisocyanatobutane
(BDI, Sigma), and putrescine.E1 Porous PEUU patches were fabricated
using a thermally induced phase separation process.E2 In brief, a 6%
(w/v) PEUU/dimethylsulfone (DMSO, Sigma) solution at 80C was
poured into a glass cylinder mold (6.5-cm inner diameter), and this
mold was placed in a 80C freezer for 3 hours, followed by immersion
in an excess volume of 70% ethanol solution at 4C to remove DMSO.
The resulting porous scaffold was immersed in an excess volume of de-
ionized water to exchange the solvent, frozen at 80C, and dried in a ly-
ophilizer for 3 days. The cylindrical scaffold was carefully sliced into
circular PEUU patches of 800-mm thickness using a delicatessen slicer.
The formed PEUU patches were immersed in 70% ethanol solution for
30 minutes, followed by 33 rinses in phosphate-buffered saline and ex-
posure bilaterally to an ultraviolet light source for 2 hours before
implantation.
Scaffold Characterization
The scaffold microstructure was observed under scanning electron mi-
croscopy (model JSM6330F; JEOL Ltd, Tokyo, Japan) and the pore size
was measured using ImageJ software (National Institutes of Health, Be-
thesda, Md). The scaffold porosity was determined in pure ethanol using
a liquid displacement method.E2 Uniaxial tensile properties were mea-
sured using 5 samples (5 3 25 mm) with a cross-head speed of 25
mm/min according to ASTM D638-98. A cyclic tensile test was per-
formed with a maximum strain of 30% and a cross-head speed of 25
mm/min. A total of 10 stretching curve cycles were recorded.
TABLE E1. Procedural details
No. Status at catheterization Outcome VT* Vf* Need DC* Euthanasiay Group
1ex Small MI Yes —
2 MIþPEUU
3 MIþPEUU
4 MIþsham
5 Yes Yes MIþsham
6 MIþPEUU
7 MIþPEUU
8 Yes No MIþsham
9 MIþsham
10ex Refractory Vfz Lost at cath. Yes Yes —
11ex Sudden deathyy MIþsham
12ex Refractory Vfx Lost at cath. Yes Yes Yes —
13ex Refractory Vfjj Lost at cath. Yes Yes —
14ex Refractory Vfjj Lost at cath. Yes Yes —
15 MIþsham
16ex Refractory Vf{ Lost at cath. Yes Yes —
17ex Small MI Yes —
18 Yes Yes MIþPEUU
19 MIþPEUU
20 MIþsham
21ex Refractory Vf# Lost at cath. Yes Yes Yes —
22ex Cardiac arrest** Lost at cath. No No —
23 MIþPEUU
24 MIþsham
25 MIþsham
VT,Ventricular tachycardia; Vf, ventricular fibrillation;DC, direct-current shock; ex, excluded from the study; Cath, catheterization;MI,myocardial infarction; PEUU, ploy(ester
urethane)urea. *Events at catheterization procedure. yEuthanasia before reaching end point. zJust after the coronary occlusion followed by cardiac arrest. xVTat balloon deflation
transitioned into Vf and cardiac arrest. jjVf at balloon deflation followed by cardiac arrest. {Vf during coronary occlusion occurred at 34 minutes. #VT 10 minutes after starting
coronary occlusion transitioned into Vf and arrest. **Sudden cardiac arrest at balloon inflation. yySudden death 2 weeks after thoracotomy.
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